Biotech Startup Exsure Secures ₹3 Crore in Seed Funding
Exsure, a biotechnology startup, has successfully raised ₹3 crore in a seed funding round led by Unicorn India Ventures. The new investment will be allocated towards:
- Completing the non-clinical study of its exosome-based drug delivery platform.
- Supporting global expansion initiatives with proprietary manufactured R&D products.
- Promoting its product offerings, such as Exosure, Leucosure, PlantExosure, and Dr. Berries.
Co-founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure is dedicated to minimising the side effects and toxicity associated with anti-cancer treatments. The company employs a patented exosomal drug delivery platform that specifically targets both cancer and cancer stem cells. Exsure aims to:
- Reduce the adverse effects of chemotherapy.
- Decrease the chances of cancer recurrence.
- Enhance the overall quality of life for cancer patients.
In the past year, Exsure has commenced a non-clinical study in India in partnership with a Contract Research Organisation (CRO) and successfully completed preclinical studies leveraging its patented technology. The startup has also launched its initial range of in-house manufactured products and established collaborations and partnerships across India for its offerings and services.
Market research indicates that the Indian biotechnology sector is projected to reach $150 billion by 2025, with the potential for further growth to between $270–300 billion by 2030.
Based in Bhubaneswar, Exsure has reported a fivefold increase in growth over the last fiscal year and is poised to serve over 50 clients this year with its R&D products, including:
- Exosure: A 3-in-1 exosome isolation reagent.
- Leucosure: A PBMC isolation reagent.
- PlantExosure: India’s first plant exosome isolation reagent.
Moreover, Exsure has been selected to participate in the OIST Innovation Accelerator Program in Japan, which aims to support its business expansion and facilitate clinical trials.